Cargando…

Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings

OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II study (NCT00548405), alemtu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Coles, Alasdair J., Cohen, Jeffrey A., Fox, Edward J., Giovannoni, Gavin, Hartung, Hans-Peter, Havrdova, Eva, Schippling, Sven, Selmaj, Krzysztof W., Traboulsee, Anthony, Compston, D. Alastair S., Margolin, David H., Thangavelu, Karthinathan, Chirieac, Madalina C., Jody, Darlene, Xenopoulos, Panos, Hogan, Richard J., Panzara, Michael A., Arnold, Douglas L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595276/ https://www.ncbi.nlm.nih.gov/pubmed/28835403 http://dx.doi.org/10.1212/WNL.0000000000004354

Ejemplares similares

Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy
por: Havrdova, Eva, et al.
Publicado: (2017)

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
por: Coles, Alasdair J., et al.
Publicado: (2021)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
por: Arnold, Douglas L., et al.
Publicado: (2016)

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study
por: Wray, Sibyl, et al.
Publicado: (2018)

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis
por: Phelps, Richard, et al.
Publicado: (2019)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management
por: Cuker, Adam, et al.
Publicado: (2019)

Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
por: Coles, Alasdair J, et al.
Publicado: (2021)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years
por: Horáková, Dana, et al.
Publicado: (2020)

Clinical pharmacology of alemtuzumab, an anti‐CD52 immunomodulator, in multiple sclerosis
por: Li, Z., et al.
Publicado: (2018)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Case of alemtuzumab-related alopecia areata management in MS
por: Chan, Jillian K., et al.
Publicado: (2018)

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
por: Steingo, Brian, et al.
Publicado: (2020)

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies
por: Van Wijmeersch, Bart, et al.
Publicado: (2019)

Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic
por: Jure Hunt, David, et al.
Publicado: (2020)

Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features
por: Pariani, Nadia, et al.
Publicado: (2018)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Detecting and predicting neutralization of alemtuzumab responses in MS
por: Saxena, Gauri, et al.
Publicado: (2020)

Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study
por: Freedman, Mark S, et al.
Publicado: (2018)

A cell-based assay for the detection of neutralizing antibodies against alemtuzumab
por: Ali, Liaqat, et al.
Publicado: (2020)

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab
por: Wiendl, Heinz, et al.
Publicado: (2019)

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study
por: Ziemssen, Tjalf, et al.
Publicado: (2020)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Future MS care: a consensus statement of the MS in the 21st Century Steering Group
por: Rieckmann, Peter, et al.
Publicado: (2012)

Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study
por: Wray, Sibyl, et al.
Publicado: (2022)

Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENA
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2017)

Repopulation of T, B, and NK cells following alemtuzumab treatment in relapsing-remitting multiple sclerosis
por: Gilmore, Wendy, et al.
Publicado: (2020)

The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies
por: Baker, David, et al.
Publicado: (2020)

Alemtuzumab induction therapy in solid organ transplantation
por: Friend, Peter J
Publicado: (2013)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ioe9gmg8ikgttb4h8dcm5qjmcp